VAPO - Vapotherm, Inc.

NYSE - NYSE Delayed Price. Currency in USD
29.00
+1.92 (+7.09%)
At close: 4:00PM EDT

29.00 0.00 (0.00%)
After hours: 4:15PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close27.08
Open27.61
Bid27.53 x 1200
Ask28.89 x 1100
Day's Range27.60 - 30.30
52 Week Range6.86 - 30.82
Volume1,227,240
Avg. Volume660,167
Market Cap622.25M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.29
Earnings DateJul 22, 2020 - Jul 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Vapotherm to Expand Production Capacity in Advance of Potential Increase in Demand for High-Flow Nasal Cannula Systems for Treating COVID-19 Respiratory Distress
    Business Wire

    Vapotherm to Expand Production Capacity in Advance of Potential Increase in Demand for High-Flow Nasal Cannula Systems for Treating COVID-19 Respiratory Distress

    Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients suffering from respiratory distress, today announced a major expansion in its capital equipment manufacturing capabilities. This expansion is expected to enable the company to increase production of its Precision Flow® systems by up to 20X above pre-COVID-19 pandemic levels. At maximum capacity, Vapotherm’s manufacturing increase would create up to an additional 350 manufacturing jobs at its New Hampshire facility. This scaling up is in response to a potential increase in demand for the company’s Precision Flow Hi-VNI® system in the event of additional waves of COVID-19. The Precision Flow Hi-VNI system is an advanced high-flow nasal cannula (HFNC) system using high velocity to treat the respiratory distress experienced by COVID-19 patients.

  • Vapotherm to Present at the William Blair 40th Annual Growth Stock Conference
    Business Wire

    Vapotherm to Present at the William Blair 40th Annual Growth Stock Conference

    Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020 via webcast.

  • Vapotherm to Present at the Bank of America Securities Virtual Health Care Conference 2020
    Business Wire

    Vapotherm to Present at the Bank of America Securities Virtual Health Care Conference 2020

    Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Bank of America Securities Health Care Conference 2020 on Thursday, May 14, 2020 via webcast.

  • 5 Reasons Why Vapotherm Will Keep Climbing
    Motley Fool

    5 Reasons Why Vapotherm Will Keep Climbing

    Vapotherm (NYSE: VAPO) is that rare company that not only had a good start to the year, it's seeing things get even better because of the coronavirus pandemic. The Exeter, N.H., medical technology company specializes in products to treat respiratory diseases. When COVID-19 hit, though, sales of the company's high-velocity nasal insufflation (Hi-VNI) technology really took off.

  • Vapotherm Announces Pricing of Public Offering of Common Stock
    Business Wire

    Vapotherm Announces Pricing of Public Offering of Common Stock

    Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of an underwritten public offering of 3,350,000 shares of its common stock at a price to the public of $26.00 per share. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares of its common stock at the public offering price less underwriting discounts and commissions. All of the shares are being offered by Vapotherm. The offering is expected to close on May 11, 2020, subject to customary closing conditions.

  • Why Vapotherm Stock Soared 34.2% Today
    Motley Fool

    Why Vapotherm Stock Soared 34.2% Today

    Shares of Vapotherm (NYSE: VAPO), a medical technology company, jumped 34.2% on Wednesday, after it reported its fiscal first-quarter earnings. Vapotherm’s services are in high demand during the COVID-19 pandemic because of one of its devices. During the first quarter, Vapotherm’s revenue was $19.1 million, a 55.4% year-over-year increase.

  • Vapotherm Announces Proposed Public Offering of Common Stock
    Business Wire

    Vapotherm Announces Proposed Public Offering of Common Stock

    Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of $75 million of its shares of common stock. All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15 percent of the number of shares sold in the offering.

  • Vapotherm Inc (VAPO) Q1 2020 Earnings Call Transcript
    Motley Fool

    Vapotherm Inc (VAPO) Q1 2020 Earnings Call Transcript

    Good afternoon, and thank you for joining us for the Vapotherm first quarter 2020 financial results conference call. Joining us on today's call are Vapotherm's President and Chief Executive Officer, Joe Army; and its Vice President and Chief Financial Officer, John Landry.

  • Vapotherm (VAPO) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Vapotherm (VAPO) Reports Q1 Loss, Tops Revenue Estimates

    Vapotherm (VAPO) delivered earnings and revenue surprises of -17.86% and 1.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Vapotherm Reports First Quarter 2020 Financial Results
    Business Wire

    Vapotherm Reports First Quarter 2020 Financial Results

    Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced first quarter 2020 financial results.

  • Are You Looking for a Top Momentum Pick? Why Vapotherm (VAPO) is a Great Choice
    Zacks

    Are You Looking for a Top Momentum Pick? Why Vapotherm (VAPO) is a Great Choice

    Does Vapotherm (VAPO) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Will Vapotherm Continue to Surge Higher?
    Zacks

    Will Vapotherm Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Vapotherm

  • Business Wire

    Vapotherm to Report First Quarter 2020 Financial Results

    Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2020 after the close of trading on Tuesday, May 5, 2020. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.

  • Vapotherm Reports Preliminary First Quarter 2020 Financial Results
    Business Wire

    Vapotherm Reports Preliminary First Quarter 2020 Financial Results

    Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced certain preliminary first quarter of 2020 financial results.

  • FDA Grants Vapotherm® Oxygen Assist Module (OAM™) Breakthrough Device Designation
    Business Wire

    FDA Grants Vapotherm® Oxygen Assist Module (OAM™) Breakthrough Device Designation

    Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that the U.S. Food and Drug Administration (FDA) recently granted Breakthrough Device Designation for the Company’s Oxygen Assist Module (OAM).

  • Vapotherm Provides Business Update in Response to COVID-19 Pandemic
    Business Wire

    Vapotherm Provides Business Update in Response to COVID-19 Pandemic

    Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced an update on their business in response to the COVID-19 pandemic.

  • Vapotherm Reports Fourth Quarter and Fiscal Year 2019 Financial Results
    Business Wire

    Vapotherm Reports Fourth Quarter and Fiscal Year 2019 Financial Results

    Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced fourth quarter and fiscal year 2019 financial results.

  • ACCESSWIRE

    Vapotherm, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 4, 2020 / Vapotherm, Inc. (VAPO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 4, 2020 at 4:30 PM Eastern Time. ...

  • CVS Health's Selling Seasons Strong, Omnicare Arm Upsets
    Zacks

    CVS Health's Selling Seasons Strong, Omnicare Arm Upsets

    CVS Health's (CVS) 2020 PBM selling season remains strong with gross new business and net new business wins.